DA-9701

a Gastrointestinal Agent formulated with Pharbitis Semen and Corydalis Tuber as a safe and effective therapeutic for functional dyspepsia patients with abnormalities in GI motor function

Networked: 22 relevant articles (6 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Son, Miwon: 7 articles (12/2018 - 10/2008)
2.	Lee, Oh Young: 4 articles (01/2017 - 03/2014)
3.	Kim, Nayoung: 3 articles (04/2022 - 04/2016)
4.	Lee, Dong Ho: 3 articles (04/2022 - 07/2015)
5.	Park, Hyojin: 3 articles (07/2016 - 07/2015)
6.	Choi, Myung-Gyu: 3 articles (04/2016 - 07/2013)
7.	Rhee, Poong-Lyul: 3 articles (04/2016 - 07/2014)
8.	Lee, Tae Ho: 3 articles (07/2014 - 10/2008)
9.	Shin, Cheol Min: 2 articles (04/2022 - 01/2018)
10.	Jin, Mirim: 2 articles (12/2018 - 10/2008)

Related Diseases

1.	Dyspepsia (Indigestion) 10/01/2008 - "To develop a therapeutic for functional dyspepsia (FD), a prokinetic agent, DA-9701 has been newly formulated with Pharbitis Semen and Corydalis Tuber and we evaluated the gastroprokinetic effects of DA-9701 in comparison with conventional prokinetics. " 12/13/2018 - "DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia." 12/01/2017 - "DA-9701, a newly developed prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber, has been shown to effectively treat functional dyspepsia. " 08/17/2017 - "Pharbitis Nil (PN) is used as a main component of the existing drug, DA-9701, which was developed to treat functional dyspepsia (FD) in Korea. " 04/30/2016 - "DA-9701 improves global and individual symptoms and increases dyspepsia-specific quality of life in patients with FD. "
2.	Parkinson Disease (Parkinson's Disease) 11/01/2020 - "This study aimed to assess the efficacy of DA-9701 on gastrointestinal symptom-related quality of life in patients with Parkinson's disease on stable dopaminergic medications. " 11/01/2020 - "Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study." 01/01/2018 - "To evaluate the effect of DA-9701, a novel prokinetic drug, on gastric motility evaluated by magnetic resonance imaging in patients with Parkinson's disease (PD). " 01/01/2018 - "DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial." 01/01/2015 - "DA-9701, a new botanical gastroprokinetic agent, has potential for the management of delayed gastric emptying in Parkinson's disease if it has no central anti-dopaminergic activity. "
3.	Esophagitis 07/31/2014 - "Although NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores compared with the placebo." 07/31/2014 - "We assessed the efficacy of DA-9701 in symptomatic patients with minimal change esophagitis. " 07/31/2014 - "Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study." 07/31/2014 - "Patients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive either DA-9701 30 mg or placebo t.i.d. "
4.	Body Weight (Weight, Body) 11/13/2021 - "DA-9701 improved GI contractility without affecting blood sugar and body weight in diabetic mice. " 11/13/2021 - "DA-9701 showed a dose-dependent increase in the amplitude of spontaneous phasic contractions in the antrum, ileum, and colon in diabetic mice without influencing body weight or blood glucose levels. "
5.	Hypersensitivity (Allergy) 04/30/2016 - "DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human studies. " 07/01/2014 - "The aim of this study was to evaluate the effect of DA-9701 on colorectal distension (CRD)-induced visceral hypersensitivity in a rat model. " 07/01/2014 - "The administration of DA-9701 resulted in a significant increase in pain threshold in rats with CRD-induced visceral hypersensitivity." 07/01/2014 - "Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model." 05/30/2013 - "DA-9701 also showed an analgesic effect in rats with colorectal distension induced visceral hypersensitivity and an antinociceptive effect in beagle dogs with gastric distension-induced nociception. "

Related Drugs and Biologics

1.	Pantoprazole (Protonix)
2.	itopride
3.	Blood Glucose (Blood Sugar)
4.	corydaline
5.	Analgesics (Analgesic Drugs)
6.	Adrenocorticotropic Hormone (ACTH)

Related Therapies and Procedures

1.	Therapeutics